AstraZeneca(US:AZN) Shang Wu Bu Wang Zhan·2025-09-26 02:52Group 1 - AstraZeneca has confirmed the suspension of its £200 million expansion plan in Cambridge, following the cancellation of a £650 million investment plan in the UK [1] - The company previously announced the cancellation of its Liverpool project in January 2023, indicating a trend of reduced investment in the UK pharmaceutical sector [1] - Merck has also halted plans to establish a new research center in London, citing a lack of investment in the life sciences sector and low valuations of innovative drugs and vaccines by successive UK governments [1] Group 2 - The UK pharmaceutical industry has been facing challenges, with calls from executives for better commercial terms from European governments to ensure fair returns on innovation [1] - The CEO of the UK Pharmaceutical Industry Association emphasized the need for a commercial environment that rewards pharmaceutical innovation and benefits UK patients [1] - A recent report from the UK Pharmaceutical Industry Association and PwC indicates that the UK's pharmaceutical R&D investment has lagged behind global trends, with a growth rate of 1.9% since 2020 compared to a global average of 6.6% [2]